Remove Collective Remove Conditions Remove Data Remove Topical
article thumbnail

Data Analysis Yields Insights Into Medical Cannabis Use, Efficacy

Cannabis Law Report

Just about any industry benefits greatly from the proper use and evaluation of data. The tech giants of today are built mostly on data regarding their users, and advertisers rely on that data to more effectively target their efforts. How to Use the Data. Advantages of Data, Macro, and Micro. RYAH Group Inc.

Data 105
article thumbnail

Report: Gen Z Would Rather Smoke Cannabis Than Consume Alcohol

Veriheal

By engaging individuals across various age groups and demographics, we gather insights into usage patterns, medical conditions, past substance experiences, and more. We have also used some information provided by New Frontier Data in 2022, which referenced various studies and findings on this age demographic’s substance use.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Washington: WSLCB Publish Their 2019 Cannabis Topics & Trends Alerts

Cannabis Law Report

Leaf Data Systems Update. WAC 315-55-018 prohibits discounts between the manufacturing and retailer tiers and WAC 314-55-017 prohibits processors from requiring the purchase of other products as a condition of a transaction. Licenses are to report both the calculated tax amount and the amount of additional collected tax.

Topical 65
article thumbnail

Study shows CBD can modify your high

The Cannigma

These conditions are aimed to control any factors that might influence the results, also known as confounding variables. THC scores were also higher than placebo scales for psychotomimetic (psychotic-like) conditions such as mania, paranoia, and cognitive disorganization. CBD alters the subjective effects of THC.

CBD 139
article thumbnail

FDA Issues Warning Letters to CBD Manufacturers Making “Over-The-Line” Health Claims

Canna Law Blog

For a complete list of questions and topics identified by the FDA, see here. The warning letters were released just a few days following Gottlieb’s testimony to a Senate subcommittee, in which he announced that his agency would use enforcement discretion against CBD product manufacturers who are making “over-the-line claims.”.

CBD 93
article thumbnail

Cannabis consumers, real-world data, and why it matters

The Cannigma

The Cannigma has always taken a data-informed approach to content creation – though up until recently we’ve been primarily leaning on the existing peer-reviewed literature to guide our content. We need more data – human data – on specific applications for the plant – symptoms, use cases, conditions and patient types.

Data 88
article thumbnail

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Puff Puff Post

INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. About INM-755: INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases.